Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, June 11, 2010 - MenHibrix

Food and Drug Administration, Center for Biologics Evaluation and Research
Office of Vaccines Research and Review Division of Vaccines and Related Product Applications Bacterial Products Department, HFM-481
Telephone: 301-827-5371

TELEPHONE CONVERSATION RECORD


 

DATE:                          JUNE 11, 2010
TIME:                           2:00 PM

CBER REP’S:              JOSEPH TEMENAK


ORGANIZATION/ REP’S: GSK Biologicals, S.A. – Jody Gould

TELEPHONE NO:          ------(b)(4)------

SUBJECT:                    GSK was informed that their original BLA submission for MenHibrix will receive a Completer Response (CR letter) prior to the action date for the submission June 12, 2010. The telecon was initiated by FDA.

Reference Number:    BLA (original) 125363

SUMMARY OF DISCUSSION:

The discussion with GSK was initiated to inform them that FDA would issue a Complete
Response (CR) letter to the MenHibrix BLA.

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English